Literature DB >> 3547723

Lobular carcinoma in situ of the breast.

E R Frykberg, F Santiago, W L Betsill, P H O'Brien.   

Abstract

Lobular carcinoma in situ of the breast is a well defined pathologic entity which is found in about 2.5 per cent of all specimens of the breast taken for biopsy and most commonly occurs in premenopausal females. Its diagnosis is virtually always incidental due to the absence of any clinical indication of its presence. This lesion carries a significant risk for development of subsequent invasive carcinoma which applies equally to both breasts and which appears to increase with time. The appropriate treatment of this disease remains a controversial issue. Various aspects of its epidemiology, pathology and natural history which have an important bearing on the therapeutic decision as well as the many treatment options available are analyzed herein. There is certainly a perception that lobular carcinoma in situ represent the early form of a malignant process which can be cured or prevented if appropriately treated at this stage. At the very least, an understanding of this lesion holds the potential for broadening our understanding of the physiologic basis of carcinoma of the breast as a whole.

Entities:  

Mesh:

Year:  1987        PMID: 3547723

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  11 in total

1.  Loss of heterozygosity in lobular carcinoma in situ of the breast.

Authors:  S R Lakhani; N Collins; J P Sloane; M R Stratton
Journal:  Clin Mol Pathol       Date:  1995-04

Review 2.  Rating the risk factors for breast cancer.

Authors:  S Eva Singletary
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

3.  Interpretation of the risk associated with the unexpected finding of lobular carcinoma in situ.

Authors:  S Zurrida; C Bartoli; V Galimberti; R Raselli; L Barletta
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

4.  Risk of contralateral breast cancer among women with carcinoma in situ of the breast.

Authors:  L A Habel; R E Moe; J R Daling; S Holte; M A Rossing; N S Weiss
Journal:  Ann Surg       Date:  1997-01       Impact factor: 12.969

Review 5.  Management of in situ and minimally invasive breast carcinoma.

Authors:  E R Frykberg; K I Bland
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

Review 6.  Current management of carcinoma of the breast.

Authors:  T J Eberlein
Journal:  Ann Surg       Date:  1994-08       Impact factor: 12.969

Review 7.  Clinical decision-making in early breast cancer.

Authors:  C M Balch; S E Singletary; K I Bland
Journal:  Ann Surg       Date:  1993-03       Impact factor: 12.969

8.  Lobular carcinoma in situ: observation without surgery as an appropriate therapy.

Authors:  W Carson; E Sanchez-Forgach; P Stomper; R Penetrante; T N Tsangaris; S B Edge
Journal:  Ann Surg Oncol       Date:  1994-03       Impact factor: 5.344

9.  Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice.

Authors:  Patrick W B Derksen; Tanya M Braumuller; Eline van der Burg; Marten Hornsveld; Elly Mesman; Jelle Wesseling; Paul Krimpenfort; Jos Jonkers
Journal:  Dis Model Mech       Date:  2011-01-31       Impact factor: 5.758

10.  The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ.

Authors:  D Robinson; L Holmberg; H Møller
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.